BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia

被引：3
|
作者：
Hogdal, Leah [1 ]
Chyla, Brenda [2 ]
McKeegan, Evelyn [2 ]
Leverson, Joel [2 ]
Potluri, Jalaja [2 ]
Falotico, Nancy [2 ]
Ricker, Justin [2 ]
Humerickhouse, Rod [2 ]
Mabry, Mack [2 ]
Foight, Glenna [3 ]
Keating, Amy [3 ]
Galinsky, Ilene [1 ]
Stone, Richard [1 ]
DeAngelo, Daniel [1 ]
Konopleva, Marina [4 ]
Letai, Anthony [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Abbvie Inc, N Chicago, IL USA
[3] MIT, Cambridge, MA 02139 USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-2834
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2834
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Salles, Gilles Andre
    Boyd, Thomas E.
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Lymp, James
    Hilger, James
    Vosganian, Gregory
    Huang, Jane
    Stilgenbauer, Stephan
    BLOOD, 2014, 124 (21)
  • [22] A phase 2 open-label study of the efficacy of ABT-199 (GDC-0199) in patients with relapsed or refractory (R/R) chronic lymphosytic leukemia (CLL) harboring 17p deletion
    Wierda, William G.
    Seymour, John Francis
    Roberts, Andrew Warwick
    Puvvada, Soham
    Davids, Matthew Steven
    Wong, Shekman
    Zhu, Ming
    Carrl, Elisa
    Humerickhouse, Rod
    Stilgenbauer, Stephan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.
    Ma, Shuo
    Seymour, John Francis
    Lanasa, Mark C.
    Kipps, Thomas J.
    Barrientos, Jacqueline Claudia
    Davids, Matthew Steven
    Mason-Bright, Tanita
    Rudersdorf, Nikita
    Yang, Jianning
    Munasinghe, Wijith
    Zhu, Ming
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod
    Roberts, Andrew Warwick
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Seymour, John Francis
    Davids, Matthew Steven
    Pagel, John M.
    Kahl, Brad S.
    Wierda, William G.
    Miller, Thomas P.
    Gerecitano, John F.
    Kipps, Thomas J.
    Anderson, Mary Ann
    Huang, David C. S.
    Darden, David E.
    Gressick, Lori A.
    Nolan, Cathy E.
    Yang, Jianning
    Busman, Todd A.
    Graham, Alison M.
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod A.
    Roberts, Andrew Warwick
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] An immunoassay detecting Bcl-2: Bim and Mcl-1: Bim complexes in the phase 1 monotherapy study of the Bcl-2 inhibitor, ABT-199/GDC-0199, in chronic lymphocytic leukemia patients
    Li, Jessica
    Chen, Jun
    Kadel, Ward
    Chyla, Brenda
    McKeegan, Evelyn
    Punnoose, Elizabeth
    Darbonne, Walter
    CANCER RESEARCH, 2014, 74 (19)
  • [26] Measuring Mitochondrial Apoptotic Priming by BH3 Profiling Predicts Induction Outcome for Acute Myeloid Leukemia Patients
    Vo, Thanh-Trang T.
    Stone, Richard
    DeAngelo, Daniel J.
    Frattini, Mark G.
    Letai, Anthony G.
    BLOOD, 2011, 118 (21) : 109 - 109
  • [27] Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells
    Pallis, Monica
    Burrows, Francis
    Ryan, Jeremy
    Grundy, Martin
    Seedhouse, Claire
    Abdul-Aziz, Amina
    Montero, Joan
    Letai, Anthony
    Russell, Nigel
    ONCOTARGET, 2017, 8 (10) : 16220 - 16232
  • [28] Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Salles, Gilles A.
    Boyd, Thomas E.
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Hallek, Michael
    Eichhorst, Barbara F.
    Kozloff, Mark
    Cartron, Guillaume
    Li, Yan
    Hilger, James
    Mobasher, Mehrdad
    Stilgenbauer, Stephan
    BLOOD, 2015, 126 (23)
  • [29] Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)
    Flinn, Ian W.
    Brunvand, Mark
    Choi, Michael Y.
    Dyer, Martin J. S.
    Gribben, John
    Hillmen, Peter
    Jones, Jeffrey
    Li, Yan
    Mobasher, Mehrdad
    Vosganian, Gregory
    Kipps, Thomas J.
    BLOOD, 2015, 126 (23)
  • [30] Macs - a Leukemic Stem Cell- Based Predictor of Clinical Response to Venetoclax and Other BH3 Mimetics for Acute Myeloid Leukemia
    Renders, Simon
    Waclawiczek, Alexander
    Leppa, Aino-Maija
    Reyneri, Cecilia
    Betz, Barbara
    Stumpf, Karolin
    Janssen, Maike
    Unglaub, Julia M.
    Donato, Elisa
    Shahswar, Rabia
    Raffel, Simon
    Heuser, Michael
    Schlenk, Richard F.
    Hundemer, Michael
    Sauer, Tim
    Muller-Tidow, Carsten
    Trumpp, Andreas
    BLOOD, 2022, 140 : 2023 - 2024
12345